Algert Global LLC Decreases Position in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Algert Global cut its Dianthus Therapeutics position by 53.4% in the second quarter, leaving the fund with 20,690 shares worth approximately $2.02 million. Institutional investors collectively own 47.53% of DNTH.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $124.27; recent targets range from $122 to $131.
• Insiders have been selling shares, including CEO Marino Garcia’s $17.95 million sale, while Dianthus reported a quarterly EPS loss of $0.90 that missed estimates despite revenue exceeding expectations.

Algert Global LLC decreased its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 53.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 20,690 shares of the company's stock after selling 23,708 shares during the period. Algert Global LLC's holdings in Dianthus Therapeutics were worth $2,017,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in DNTH. Elevation Point Wealth Partners LLC purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth about $868,000. Quantbot Technologies LP acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $174,000. Emerald Investment Advisers LLC purchased a new position in Dianthus Therapeutics during the 2nd quarter valued at about $2,579,000. E Fund Management Co. Ltd. purchased a new position in Dianthus Therapeutics during the 2nd quarter valued at about $497,000. Finally, Eagle Health Investments LP acquired a new position in Dianthus Therapeutics during the second quarter worth about $12,803,000. Hedge funds and other institutional investors own 47.53% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on DNTH. Wedbush increased their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. Truist Financial lifted their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Guggenheim reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reiterated an "outperform" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Raymond James Financial reissued a "strong-buy" rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $124.27.

Insider Buying and Selling at Dianthus Therapeutics

In related news, CEO Marino Garcia sold 166,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the transaction, the chief executive officer directly owned 65,292 shares in the company, valued at approximately $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Simon Read sold 2,778 shares of the firm's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the sale, the director directly owned 2,778 shares in the company, valued at approximately $326,553.90. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 287,084 shares of company stock valued at $29,615,923. 3.02% of the stock is currently owned by insiders.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $105.84 on Friday. The firm has a 50 day simple moving average of $103.59 and a 200-day simple moving average of $87.08. The firm has a market cap of $5.79 billion, a PE ratio of -25.50 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 1-year low of $22.81 and a 1-year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source